Half-Year 2022 Financial and Clinical Trials Update

Core Lab CHFbn 4.8 4.0 3.2 2.4 1.6 0.8 2022 vs. 2021 CER growth +4% HY 2022 0.0 HY 2020 HY 2021 Immunodiagnostics Clinical Chemistry CER=Constant Exchange Rates; underlying growth of Core Lab excluding Roche Information Solutions: +4% Other -7% +8% +6% Roche 190

View entire presentation